Long-term evaluation of advanced Parkinson’s disease burden and clinical outcomes: results from the PROSPECT observational study
Objective: Evaluate long-term clinical outcomes and disease burden in people with advanced Parkinson's disease (PwP) with motor fluctuations not optimized by their current medications. Background:…Characterization of Infusion Site Reactions With 24-hour Subcutaneous Infusion of ND0612
Objective: To characterize infusion site reactions (ISRs) reported as adverse events (AEs) in clinical studies of ND0612. Background: ND0612 is an investigational, subcutaneous infusion of…Intrinsic Auricular Muscle Zone Stimulation for Moderate-to-Severe Parkinson’s Disease
Objective: To assess the effects of electrical stimulation of the Intrinsic Auricular Muscle Zone (IAMZ) on motor symptoms in patients with moderate-to-severe Parkinson’s disease (PD).…WATCH-PD2: A Remote Extension Digital Measures Study in Early Parkinson’s Disease: Study Design and Status Update
Objective: To evaluate longitudinal change in WATCH-PD digital measures in a remote extension study in order to maximize learnings and inform use of digital measures…Retention Strategies in Parkinson’s Disease Clinical Studies: Findings From a Scoping Review of Recruitment and Retention Strategies
Objective: To understand successful recruitment and retention strategies for clinical research studies in Parkinson’s disease (PD) Background: Half of all clinical trials do not reach…Predictability of Motor States With Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson’s Disease
Objective: To assess predictability of “On” or “Off” motor states in patients (pts) with advanced Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDp/CDp). Background: Pts with…Continuous Subcutaneous Apomorphine Infusion for Parkinson Disease Motor Fluctuations: Long-Term Data from the Ongoing InfusON Extension Study
Objective: Evaluate outcomes (up to 3 years) from the ongoing Extension Period of the InfusON study (NCT02339064) of continuous subcutaneous apomorphine infusion (CSAI). Background: Primary…Exploring the Neuroprotective Potential of Mushroom Extracts in Parkinson’s Disease In-Vitro Models
Objective: This study investigates the potential neuroprotective effects of several mushroom extracts in PD in-vitro models. Background: Parkinson's disease, a progressive condition, involves dysfunction or…Novel In-Clinic Use of Levodopa Inhalation Powder (CVT-301) as an Outpatient Diagnostic Tool for Parkinson’s Disease
Objective: The clinical diagnosis of PD is based on demonstration of major motor manifestations on the neurologic exam, however, levodopa-responsiveness can be a very helpful…Real-World Multicenter Analysis of Levodopa Equivalent Daily Dosage Algorithms- Capturing Geographical and Demographic Disparities in Parkinson’s Disease Therapy Spanning Six Countries and Two Continents
Objective: To assess the influence of updated Levodopa Equivalent Daily Dosage (LEDD) conversion factors in capturing the newer therapies in Parkinson’s Disease (PD) and therapy…
- « Previous Page
- 1
- …
- 243
- 244
- 245
- 246
- 247
- …
- 553
- Next Page »